Davis R M Inc. Reduces Holdings in Hologic, Inc. (NASDAQ:HOLX)

Davis R M Inc. decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 9.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,259 shares of the medical equipment provider’s stock after selling 439 shares during the quarter. Davis R M Inc.’s holdings in Hologic were worth $347,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Innealta Capital LLC acquired a new stake in shares of Hologic in the 2nd quarter valued at about $25,000. Wolff Wiese Magana LLC acquired a new stake in shares of Hologic in the third quarter valued at approximately $25,000. iA Global Asset Management Inc. purchased a new position in shares of Hologic during the first quarter worth approximately $37,000. Sunbelt Securities Inc. purchased a new position in shares of Hologic during the second quarter worth approximately $37,000. Finally, First Horizon Advisors Inc. raised its position in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 134 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on HOLX. JPMorgan Chase & Co. raised their price objective on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Evercore ISI raised their price target on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a report on Tuesday, October 1st. Citigroup downgraded Hologic from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Leerink Partners lowered their target price on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Finally, Raymond James upped their price target on Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Trading Up 1.0 %

Shares of HOLX opened at $79.73 on Tuesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. Hologic, Inc. has a 1-year low of $67.59 and a 1-year high of $84.67. The stock has a market cap of $18.52 billion, a price-to-earnings ratio of 23.94, a price-to-earnings-growth ratio of 2.49 and a beta of 0.98. The firm has a 50 day simple moving average of $80.38 and a 200-day simple moving average of $78.38.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. During the same quarter in the prior year, the firm earned $0.89 EPS. Hologic’s quarterly revenue was up 4.5% on a year-over-year basis. Equities analysts forecast that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.